Education
Medical school: Duke University
Residency: Surgery, Harvard University/Brigham and Women's Hospital
Fellowship: Surgical Oncology, University of California
Board certification: General Surgery · Surgical Oncology
Awards
Department of Defense Breast Cancer Research Program Breakthrough Award
“The Duke” Special Service Award, John Wayne Cancer Institute Auxiliary
Premier Girls Fastpitch Research Grant Awardee, John Wayne Cancer Foundation
Memberships and affiliations
American College of Surgeons
Society of Surgical Oncology
American Society of Breast Surgeons
American Society of Clinical Oncology
Duke University School of Medicine
Clinical experience
Daily practice finds Dr. DiNome applying precision-oncology principles to a spectrum ranging from ductal carcinoma in situ to triple-negative invasive disease and hereditary risk lesions. Every new patient undergoes tomosynthesis imaging, ultrasound, and multiparametric MRI when indicated; tissue cores receive same-day molecular profiling that identifies actionable drivers such as PIK3CA or PD-L1 expression. Decision-support software matches results with targeted agents, radiation protocols, or trial slots, while physiatrists and lymphedema therapists contribute prehabilitation plans that protect arm mobility. In the operating room she employs intraoperative ultrasound guidance, radioisotope or magnetic seed localization, and fluorescence angiography to confirm perfusion before closing skin flaps. Enhanced-recovery pathways combine paravertebral blocks, non-opioid analgesia, and early protein-rich diets, letting most patients return home within twenty-four hours. Remote vital-sign monitoring and daily symptom surveys allow nurse practitioners to intervene before minor concerns escalate, and tele-visits accommodate those living far from Durham. This precision breast-surgery model translates complex science into personalized security and swift recovery.
As principal investigator on institutional and cooperative-group protocols, Dr. DiNome studies how short-course endocrine priming, checkpoint inhibitors, and cryoablation pair with breast-conserving surgery to widen options without raising toxicity. Adaptive trial designs feature serial liquid biopsies, wearable-device data, and patient-reported outcomes, allowing hypotheses to evolve when safety or efficacy signals shift. Electronic consent, courier-based specimen pickup, and virtual follow-ups let rural participants contribute without logistical strain, while weekly safety huddles unite surgeons, medical oncologists, statisticians, and patient advocates to maintain ethical vigilance. One flagship study evaluates whether image-guided axillary cryoablation can replace nodal dissection in select responders, measuring pain scores, lymph-edema incidence, and disease-free intervals. Interim analyses inform guideline committees in real time, ensuring that promising findings translate quickly into practice. This trial-leadership portfolio offers patients the reassurance of cutting-edge care governed by meticulous oversight.
Looking ahead, Dr. DiNome pilots technologies poised to redefine breast-cancer standards. Artificial-intelligence algorithms trained on annotated mammograms now flag subtle architectural distortions years before palpation, while augmented-reality overlays project tumor boundaries onto the operative field without diverting the surgeon’s gaze. Collaborative studies test radioligand therapy targeting HER2-low micrometastatic disease, and bioresorbable meshes infused with immunomodulators aim to fortify oncoplastic reconstructions against local recurrence. Health-equity audits validate each algorithm across ancestry groups, and policy teams negotiate reimbursement pathways so innovations reach diverse communities. Prospective registries track cosmesis, sensory recovery, and mental well-being alongside oncologic metrics, proving that success depends on whole-person outcomes. Patients therefore meet a surgeon who not only excels in today’s best practices but also builds the safer, more equitable therapies of tomorrow.